Riskpilot← Back to searchSign inGet full accessONCORAL PHARMA ApS
APSActiveCVR 35481214Amaliegade 6, 2. tvResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20130 employees
Revenue 2024
DKK -367K
-63% vs 2023
EBITDA margin
100.0%
+63% vs 2023
Equity ratio
-4889.2%
Financial strength
Net profit 2024
DKK -4,1M
-52% vs 2023
| Revenue | DKK -367K | -63% |
| EBITDA | DKK -367K | +63% |
| Net profit | DKK -4,1M | -52% |
| Total assets | DKK 679K | -93% |
| Equity | DKK -33,2M | -14% |
| Employees | 0 | — |
Legal name
ONCORAL PHARMA ApS
CVR number
35481214
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
25. september 2013
Share capital
DKK 145.919
Employees
0
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af hele direktionen i forening, eller af en direktør alene.
Company purpose
Selskabet har til formål at gennemføre forsknings- og udviklingsaktiviteter relateret til udvikling af lægemidler, herunder særligt lægemidler i tabletform til behandling af cancer, og at udføre aktiviteter, som efter direktionens skøn er naturligt relaterede hertil.
Address
Amaliegade 6, 2. tv
Phone
+4545484448
Email
moc@ascelia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -3.856 | -13.820 | -7.462 | -996 | -367 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3.856 | -13.820 | -7.462 | -996 | -367 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.856 | -13.820 | -7.462 | -996 | -367 |
| Net financials | -348 | -656 | -3.101 | -1.882 | -3.756 |
| Profit before tax | -4.205 | -14.476 | -10.563 | -2.878 | -4.123 |
| Tax | -747 | -2.658 | -1.356 | -211 | -65 |
| Net profit | -3.458 | -11.818 | -9.207 | -2.667 | -4.058 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.722 | 14.886 | 9.597 | 9.483 | 679 |
| Equity | -5.440 | -17.258 | -26.465 | -29.132 | -33.190 |
| Long-term debt | 7.004 | 26.653 | 28.748 | 28.362 | 32.415 |
| Short-term debt | 1.158 | 5.491 | 7.314 | 10.254 | 1.454 |
| Total debt | 8.162 | 32.144 | 36.062 | 38.615 | 33.869 |
EBITDA margin
-36678800.0%
This company
15.8%
Market median
-232144404% vs market
20202024
Equity ratio
-4889.2%
This company
38.2%
Market median
-12899% vs market
20202024
Return on equity
-405783400.0%
This company
18.4%
Market median
-2205344665% vs market
20202024
Net profit margin
-405783400.0%
This company
8.1%
Market median
-5009671705% vs market
20202024
Asset turnover
-0.54×
This company
1.12×
Market median
-148% vs market
20202024
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MO Chief Executive Officer | Chief Executive Officer | 2017 |
| Former (1) | ||
PG Management | Management | 2013 – 2017 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Chairman | 2015 – 2017 | |
| Chairman | 2013 – 2015 | |
| Board of Directors | 2013 – 2017 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2017 | |
| Company | 20–24.99% | 20–24.99% | 2016 | |
| Company | 66.67–89.99% | 66.67–89.99% | 2013 | |
| Company | 20–24.99% | 20–24.99% | 2017 | |
| Company | 5–9.99% | 5–9.99% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ONCORAL PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Gudmund Nielsen | Management | 0 companies |
| Magnus Olafsson Corfitzen | Chief Executive Officer | 0 companies |
| Mette Munch | Chairman | 0 companies |
| Jørn Frederik Falch | Chairman | 0 companies |
| Ann Vivian Fullerton | Board of Directors | 0 companies |